PE20181012A1 - NOVEDOSA DUAL DELAYED-RELEASE ORAL COMPOSITION DEXLANSOPROZOLE - Google Patents

NOVEDOSA DUAL DELAYED-RELEASE ORAL COMPOSITION DEXLANSOPROZOLE

Info

Publication number
PE20181012A1
PE20181012A1 PE2018000128A PE2018000128A PE20181012A1 PE 20181012 A1 PE20181012 A1 PE 20181012A1 PE 2018000128 A PE2018000128 A PE 2018000128A PE 2018000128 A PE2018000128 A PE 2018000128A PE 20181012 A1 PE20181012 A1 PE 20181012A1
Authority
PE
Peru
Prior art keywords
novedosa
dexlansoprozole
dexlansoprazole
release oral
pharmaceutically acceptable
Prior art date
Application number
PE2018000128A
Other languages
Spanish (es)
Inventor
Anwar Siraj Daud
Shamsuddin Jamaluddin
Original Assignee
Zim Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57884420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zim Laboratories Ltd filed Critical Zim Laboratories Ltd
Publication of PE20181012A1 publication Critical patent/PE20181012A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente revelacion proporciona una composicion farmaceutica oral de liberacion retardada dual de dexlansoprazol o sus sales aceptables para uso farmaceutico o formas hidratadas. La composicion farmaceutica de liberacion retardada dual revelada puede incorporar dos formulaciones de liberacion pulsatil (a) y (b), en donde la formulacion (a) puede incluir: (i) una particula de nucleo que comprende dexlansoprazol o una sal aceptable para uso farmaceutico o un hidrato del mismo, y (ii) una capa de liberacion controlada dependiente del pH; y la formulacion (b) puede incluir: (i) una particula de nucleo que comprende dexlansoprazol o una sal aceptable para uso farmaceutico o un hidrato del mismo, (ii) una capa de liberacion controlada independiente del pH, y (iii) una capa de liberacion controlada dependiente del pH.The present disclosure provides a dual delayed release oral pharmaceutical composition of dexlansoprazole or its pharmaceutically acceptable salts or hydrated forms. The disclosed dual delayed release pharmaceutical composition may incorporate two pulsatile release formulations (a) and (b), wherein formulation (a) may include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or a hydrate thereof, and (ii) a pH-dependent controlled release layer; and formulation (b) may include: (i) a core particle comprising dexlansoprazole or a pharmaceutically acceptable salt or hydrate thereof, (ii) a pH-independent controlled release layer, and (iii) a layer pH-dependent controlled release.

PE2018000128A 2015-07-28 2016-07-27 NOVEDOSA DUAL DELAYED-RELEASE ORAL COMPOSITION DEXLANSOPROZOLE PE20181012A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2851MU2015 2015-07-28

Publications (1)

Publication Number Publication Date
PE20181012A1 true PE20181012A1 (en) 2018-06-26

Family

ID=57884420

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000128A PE20181012A1 (en) 2015-07-28 2016-07-27 NOVEDOSA DUAL DELAYED-RELEASE ORAL COMPOSITION DEXLANSOPROZOLE

Country Status (6)

Country Link
EP (1) EP3328364A4 (en)
BR (1) BR112018001539A2 (en)
CL (1) CL2018000220A1 (en)
CO (1) CO2018002046A2 (en)
PE (1) PE20181012A1 (en)
WO (1) WO2017017615A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111991367A (en) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 Esomeprazole magnesium pulse pellet capsule and preparation method thereof
KR102471545B1 (en) * 2020-11-20 2022-11-29 서울대학교 산학협력단 pH-dependent tablet-in-capsule combination formulation containing dexransoprazole as an active ingredient and method for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (en) * 2011-12-21 2013-08-01 Hetero Research Foundation Controlled release solid oral compositions of dexlansoprazole

Also Published As

Publication number Publication date
CL2018000220A1 (en) 2018-07-20
WO2017017615A1 (en) 2017-02-02
EP3328364A1 (en) 2018-06-06
BR112018001539A2 (en) 2018-09-18
EP3328364A4 (en) 2019-01-02
CO2018002046A2 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
HRP20201812T1 (en) Hepatitis b core protein modulators
DOP2020000102A (en) HELPFUL COMPOUNDS TO INHIBIT CDK7
MX2020010484A (en) Substituted heterocyclyl derivatives as cdk inhibitors.
BR112018071585A2 (en) formulations of an lsd1 inhibitor
EA201792116A1 (en) JANUS KINASE INHIBITOR
UY35933A (en) PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AZD9291
CL2017003320A1 (en) Pharmaceutical formulations containing tenofovir and emtricitabine
EP3873905A4 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
EP3417861A4 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
CL2015003468A1 (en) Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d.
CR20160527A (en) CARBOXAMIDE DERIVATIVES
EP3400964A4 (en) Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof
IL276430A (en) Pharmaceutical compound, salts thereof, formulations thereof, and methods of making and using same
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
DOP2016000003A (en) STABILIZED PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE BACK
AR108233A1 (en) ORIC PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE
CO2018002046A2 (en) New oral delayed dual dexlansoprazole oral composition
AR097644A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING REFAMETINIB, USE AND TREATMENT METHOD
CL2018000391A1 (en) Pharmaceutical combinations and their use
AR103484A1 (en) TRIPTOLID AND ITS DERIVATIVES IN THE TREATMENT OF PRECANCER TUMORS AND SKIN PATHOLOGIES
CL2016000182A1 (en) Stable anti-tuberculosis pharmaceutical composition in a form of a coated tablet comprising isoniazid granules and rifapentin granules and their preparation process
IL261618A (en) Unit doses for immediate release of ghb or of one of the therapeutically acceptable salts thereof, administered orally, and the use thereof to maintain alcohol abstinence.
CR20190401A (en) Dropropizine in combination with ambroxol in the dosage form of syrup or tablets
TH1701003406A (en) Pharmaceutical formulation of tropomieosin-related kinase inhibitors (TRK).